In Sight: My Life in Science and Biotech

Levy, Julia

ISBN 10: 148750831X / ISBN 13: 9781487508319

Published by Rotman-UTP Publishing, 2020

About this Item

Book is in very good condition and may include minimal underlining highlighting. The book can also include "From the library of" labels. May not contain miscellaneous items toys, dvds, etc. . We offer 100% money back guarantee and 24 7 customer service.

Seller Inventory # ZBV.148750831X.VG

Bibliographic Details

• Title: In Sight: My Life in Science and Biotech
• Publisher: Rotman-UTP Publishing
• Publication Date: 2020
• Language: English
• ISBN 10: 148750831X
• ISBN 13: 9781487508319
• Binding: Hardcover
• Condition: very_good

About this title

Synopsis

In Sight is a memoir about how a love of science and discovery drove Julia Levy, a celebrated scholar and biotech CEO, to work her way through gender bias in order to achieve academic and professional recognition. Her story traces the unconventional invention of a breakthrough drug treatment from its development from laboratory research to its application as a medical treatment for vision loss.

Told from a female perspective, In Sight is a unique and personal story covering Levy’s early years as a refugee, her university training in the UK, and her appointment as professor at the University of British Columbia. Years spent as an academic led the author to unexpected exposure to the biotechnology industry and a chance meeting with colleagues that led to the formation of a lucrative biotechnology company, known today as QLT Inc. The bulk of the book covers the years spent building the company, and Levy’s surprising transition from chief scientific officer to CEO. In Sight is an honest description of the trials of drug development, the tensions inherent in the commercialization of health innovations, and the truly remarkable hurdles faced by women in the scientific community.

About the Author

Julia Levy has been a leader in the fields of science, education, and business. She served first as chief scientific officer and later as chief executive officer of QLT. During her tenure as CEO the company obtained regulatory approval for its macular degeneration treatment that resulted in the financial success of QLT Inc. She is an officer of the Order of Canada and has received a number of honorary degrees.